ATAD1 and malaria: This fusion protein was evaluated with the aim of further development as a malaria blood-stage vaccine, but there are internal proteolytic cleavage sites in the vaccine antigen, separating the MSP-119 component from the MSP-1 Block1/2 component, which led to reduced overall yields of full-length MSP-1-BBM.